New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|January 27, 2021
Supplements and Featured Publications
- Value-Based Agreements in Rare Disease: Focus on Hereditary Amyloid Transthyretin Amyloidosis
Value-Based Agreements in Rare Disease: Focus on Hereditary Amyloid Transthyretin Amyloidosis
Advertisement
The American Journal of Managed Care® hosted a scientific interchange titled “Value-Based Agreements in Rare Disease” on September 30, 2020. This publication highlights key discussion points and insights from this event.
Advertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
3
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
4
World Alzheimer Day: Young-Onset Alzheimer Disease Often Misdiagnosed
5